We would love to hear your thoughts about our site and services, please take our survey here.
Apologies CW, easy to lose track,as Bublé implies, they do seem to be hitting the conference circuit harder than normal?
Https://www.ddw-online.com/what-to-expect-from-pegs-europe-2023-day-1-26944-202311/
"Mireille Vankemmelbeke, PhD, Principal Scientist, Biodiscovery, Scancell, on: ‘Glycan and novel targets for bispecific cancer therapy’."
"...Yet people are asking,' Why don't we get pre-clinical deals like everyone else. Well because SCIB1 and Modi - 1 are actually in clinic so it is impossible to get a pre-clinical deal. Also, I would strongly suggest that we have had a pre-clinical deal of sorts (modi 1) that allows Scancell to maintain it's full rights: Redmile investment.
"Finally, I am sure that the pharma world understands exactly what Scancell are doing and when the time is right, more deals will get done."
Thanks Bojo, good points all very well made. And yes the pre-clinical is (now) kind of a moot point, but my 'argument' as such is, why hasn't they're been a pre-emptive strike of sorts yet i.e. big pharma has seen enough and don't want to risk waiting/competition jumping the gun?
I'm assuming there are NDA's in place, and I'm convinced there will be multiple parties interested in the company/portfolio.
...100k sell.
Patience of a saint rings to mind.
Agree c11, but news of any kind deal/partnering, small or large, won't obviously be provided on any outlook plan.
As violindog says .."WTP....we live in hope : ))"
I lose track of all the conference types to be honest, but this one is specifically for partnering it seems. Interesting IMO.
https://www.trade.gov/germany-events-bio-europe#:~:text=BIO%2DEurope%20is%20the%20preeminent,%2C%20pharmaceutical%2C%20and%20financial%20sectors.
Agree the Scancell science is not her remit here, there are better qualified people for the job at Scancell for that. But saying that she does also seem to have a strong science background also?
https://ceoworld.biz/directory/exec/dr-mandeep-sehmi
Many strings to her bow it seems.
And what confused me was the description, sounds more scientific, no?
"...learn about Scancell Ltd exciting and innovative approaches to immunotherapy. "
But I guess not much can be inferred from the above as it's quite generic also.
Hopefully it is to arrange specific meetings with specific people. Who do we know is in Germany?
So is she there in a science capacity or a business capacity? Whilst I believe she is a multi faceted i.e.has a science background as well, I'm trying to understand her attendance purpose.
...that Dr Semhi is attending a conference on her own in Germany about now? Can't find the details.
"...How much more data does Sclp need?. Pharmas are buying out Cos with only preclinical results. IMO"
A point I've made many times Dracula1, why do Scancell, and quite a few posters seem to adhere to the "data, data, data " mantra, when as we agree, there are so many preclinical deals? A genuine question to those posters? I.e. what makes Scancell so different? I know there has always been "maximising shareholder value" thing. But a buyout/partnership now would still achieve that to a degree?
"...Surely Sclp can't attempt to go much further with present trials with the SP where It Is."
Another good point. Surely they will get to a point and say no we need to partner to really push this forward?
You'd think they specifically hired the new business development officer Dr. Semhi for the reason of wanting to sign a deal/deals sooner rather than later?
...as my previous attempt does not seem to have saved?
"A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: efficacy and safety results from the open-label phase 2 SCOPE trial"
Will post URL in second post in case that is the issue.
https://jitc.bmj.com/content/11/Suppl_2/A1711
Wasn't it established by someone/a few posters it was a typo?
Jmc?
Good spot jb7070. Interesting 🤔
Has it been held there before ever?
Bye then.
I'm sure with the new news about the extended cash runway there are several posters so very disappointed that they can't twist the narrative of needing a cash call etc. Diddums.
Researcher - simply sell your 'holding' and come back in 18 months. Ta ra!
Anyway your posting history shows you simply trade the stock, nothing wrong with that of course. But don't try to (badly) misinterpret the RNS for your own benefit.